Precision
Dutasteride

Designed to strongly inhibit scalp 5α-reductase while minimizing systemic absorption.

1Dutasteride inhibits both type I and type II isoenzymes for powerful suppression of scalp DHT.
2Anagen's proprietary delivery vehicle causes liposomes to preferentially aggregate in a follicular reservoir for localized diffusion to dermal papilla cells.
3Early before/after patient sampling shows no serum DHT reduction.

A dropper deposits Precision Dutasteride lipid vesicles that route into the follicle, partition into the sebum reservoir, and release dutasteride that diffuses to the dermal papilla. Schematic, not to scale.

Key termStratum corneum. The skin's brick-and-mortar outer barrier, the rate-limiting step for anything applied to flat skin.

Key termFollicular reservoir. The follicle canal acts as a shunt past that barrier and a slow-release depot for the drug.

Key termConcentration gradient. By Fick's law, drug diffuses from high to low concentration; a steep local gradient drives it into the dermal papilla.

02 The Strategy

Why we deliver through the follicle.

Dutasteride is one of the most potent DHT blockers there is, but its target sits deep inside the follicle, and taken orally it suppresses DHT across the whole body. The entire job of a topical is to put that potency at the follicle and minimize systemic absorption. That's a delivery problem, and it's the one Precision Dutasteride's vehicle is built to solve.

Key term · Stratum corneumThe skin's brick-and-mortar outer barrier, the rate-limiting step for anything applied to flat skin. The follicle canal is the shunt past it.

1The target is deep and local. Inside the follicle, 5α-reductase converts testosterone into DHT, and DHT acts on the dermal papilla at the base of the follicle to miniaturize it. The drug has to reach the dermal papilla, locally, deep in the follicle.
2Flat skin blocks the way. The stratum corneum, the skin's outer "brick-and-mortar" layer (keratin cells packed in a lipid matrix), is the rate-limiting barrier to topical drugs; intact lipid vehicles essentially can't cross it.
3The follicle is the shortcut. The follicle opening bypasses that barrier: the drug and its lipid vesicles funnel down the follicular canal and pool in the sebum as a long-lived "follicular reservoir": reaching depth, and lingering, in a way flat-skin diffusion can't.
4A localized gradient does the targeting. Concentrating the drug in the follicle builds a steep local concentration gradient. By Fick's law, diffusion flows from high to low concentration: a strong push across the thin canal wall into the dermal papilla, exactly where it's needed. Because the depot is small and local, the outward gradient is weak, so little drug spreads to the deeper dermis or the bloodstream.

High exposure at the follicle, low exposure everywhere else.

That is the whole rationale for follicular targeting: the local action of dutasteride with far less of the systemic trade-off. Which is why we screened dozens of vehicles for exactly this property, and the rest of this page is the evidence the vehicle actually does it.

Figure refPlate 02. Each bar is one delivery system tested ex vivo, grouped by family and ranked. Bar length is its follicular targeting factor: how strongly it routes drug into the follicle versus the surrounding skin, at 12 h and 24 h.

Reading the plotThe dashed line marks the mineral-oil control (0.31). Anything to its right beats the simplest possible vehicle.

NoteThe winning vehicle powers Precision Dutasteride; its proprietary identity and composition remain confidential.

03 The Vehicle Screen

More than 60 delivery systems went in. One came out ahead.

A vehicle is only as good as where it puts the drug. We screened the field (liposomes, ethosomes, transfersomes, polymer nanospheres and nanocapsules, mineral carriers) for one property: routing dutasteride into the follicle.

Figure ref · Plate 02Each bar is one delivery system tested ex vivo (teal = 12 h, coral = 24 h), grouped by family and ranked. The dashed line is the mineral-oil control (0.31); anything past it beats the simplest vehicle. The winning vehicle powers Precision Dutasteride; its proprietary identity and composition remain confidential.

Plate 02Ranked field · follicular targeting factor

12 h24 h

Mineral-oil control (0.31)"—" = not measured at that timepoint · 24 h-only series noted

Plate 02. Ex-vivo follicular targeting factor (mean ± SD), porcine / rat skin, 12 h and 24 h. This is a delivery measure (how well a vehicle routes drug into the follicle), not a measure of clinical hair growth. Over 60 systems screened; the winning vehicle behind Precision Dutasteride reaches 0.64 at 12 h versus ≈ 0.47 for the best alternative.

Figure refPlate 03. Each pair of bars is one patient's serum DHT before starting Precision Dutasteride and at follow-up. The shaded band is a typical adult-male reference range.

Read honestly A follicle-local topical should leave systemic DHT largely unmoved. Stable serum DHT is the expected, reassuring result, not an efficacy claim.

04 Serum DHT

Early Precision Dutasteride patients show no decrease in serum DHT.

If the drug truly stays local, systemic DHT should barely move. Across six early patients we monitored serum DHT (ng/dL) at baseline and follow-up. This is real-world observational monitoring (n = 6), not a randomized or controlled endpoint.

Plate 03Serum DHT · baseline → follow-up (n = 6)

Mean change +10.6% (n = 6)

Minimal systemic DHT change, consistent with a follicle-local topical that leaves circulating hormone largely unmoved.

Plate 03. Real-world observational serum-DHT monitoring in early Precision Dutasteride (0.03%) patients (n = 6), baseline → follow-up, June 2026. Observational patient monitoring; not a randomized or controlled endpoint. Maxx Precision Dutasteride (0.3%) serum-DHT monitoring is ongoing, not yet reported.

Figure refPlate 04. Two compartments after dosing ex vivo: drug recovered in the follicle, and drug reaching the deeper viable skin (the receptor compartment a stand in for what could enter circulation).

Key termBelow detection (ø). Too little drug to quantify with the assay; the receptor compartment did not register a measurable amount.

05 Stays Local

In skin tests, the drug concentrates in the follicle with variability between wet and dry scalp.

Targeting only matters if the drug also stays put. Ex vivo, dutasteride accumulated in the follicle while the deeper viable-skin compartment (the path toward circulation) stayed below the assay's detection limit. More dutasteride was recovered from the follicle in wet scalp conditions compared to dry.

Figure ref · Plate 04Drug recovered in the follicle versus drug reaching the deeper viable skin (the receptor compartment, a stand in for circulation). “Below detection (ø)” means too little to quantify.

Plate 04Compartment recovery · follicle vs systemic

Plate 04. Ex vivo compartment recovery. Drug held in the follicle reached ≈ 5 µg/cm² (dry scalp) and ≈ 9 µg/cm² (wet scalp, ≈ 1.8× dry), with sustained release over time; the deeper viable skin (receptor) compartment was below the assay's detection limit in both conditions. An ex vivo measure of where the drug goes, not a clinical PK study.

Clinical context

Dutasteride's hair-growth efficacy as a dual 5α-reductase inhibitor is well established and covered in depth elsewhere. This page is about delivery: getting that established molecule into the follicle while minimizing systemic absorption.

See the dutasteride hair-science page →

06 The Bottom Line

01 · Vehicle

Targeted delivery

The winning vehicle routes drug into the follicle: 0.64 vs ≈ 0.47 for the best alternative.

Measured · ex vivo

02 · Hormone

Serum DHT unmoved

Across 6 early patients, serum DHT showed no decrease (+10.6%); stays within range.

Observed · n = 6

03 · Safety

Stays local

Drug accumulates in the follicle; the systemic route stayed below detection.

Measured · ex vivo

04 · Choice

Two strengths

Precision Dutasteride 0.03% and Maxx Precision Dutasteride 0.3%: clinician-dialed local dose.

Product

Choose your dose

Two strengths, one follicle-targeting vehicle.

A licensed clinician decides whether either is right for you.

Best Seller

Potent